BRAF V600E in a Preclinical Model of Pleomorphic Xanthoastrocytoma (PXA): Analysis of the Tumor Microenvironment and Immune Cell Infiltration dynamics in vivo.

Low-grade glioma is the most common brain tumor affecting pediatric patients (pLGG) and BRAF mutations constitute the most frequent genetic alterations. Within the spectrum of pLGGs, approximately 70-80% of pediatric patients diagnosed with transforming Pleomorphic Xanthoastrocytoma (PXA) harbor the BRAF V600E mutation. However, the impact of glioma BRAF V600E cells regulation of tumor-infiltrating immune cells and their contribution to tumor progression remains unclear. Moreover, the efficacy of BRAF inhibitors in treating pLGGs is limited compared to their impact on BRAF-mutated melanoma. Here we report a novel immunocompetent RCAS-BRAF V600E murine glioma model. Pathological assessment indicates this model appears to be consistent with diffuse gliomas and morphological features of PXA. Our investigations revealed distinct immune cells signatures associated with increased trafficking and activation within the tumor microenvironment (TME). Intriguingly, immune system activation within the TME also generated a pronounced inflammatory response associated with dysfunctional CD8+ T cells, increased presence of immunosuppressive myeloid cells and regulatory T cells (Tregs). Further, our data suggests tumor-induced inflammatory processes such as cytokine storm. These findings suggest a complex interplay between tumor progression and the robust inflammatory response within the TME in preclinical BRAF V600E LGGs, which may significantly influence animal survival.